Ocugen completes Phase 3 enrollment for gene-agnostic retinitis pigmentosa therapy
Share
Ocugen (NASDAQ:OCGN) announced Monday that it has completed patient enrollment for its pivotal Phase 3 liMeliGhT clinical trial, evaluating OCU400 for the treatment of retinitis pigmentosa (RP).
